TMCnet News
Bipolar Disorder - 5EU Drug Forecast and Market Analysis to 2024 - Research and MarketsResearch and Markets has announced the addition of the "Bipolar Disorder - 5EU Drug Forecast and Market Analysis to 2024" report to their offering. Bipolar Disorder - 5EU Drug Forecast and Market Analysis to 2024 estimate that drug sales for bipolar disorder in the 5EU reached $773.8m in 2014. The generic erosion of Otsuka's Abilify is expected to cause an initial contraction in market size between 2014 and 2016. However, the market is expected to grow starting from 2017, driven by the uptake of pipeline agents in combination with increasing diagnosis and treatment rates throughout the 5EU. The market growth is forecast to slow towards the end of the forecast period as the market uptake of both generics and pipeline products becomes established. Scope - Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including roduct description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU (France, Germany, Italy, Spain, and the UK) from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting 5EU Bipolar Disorder market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Classification 3.3 Symptoms 4 Disease Management 4.1 Diagnosis Overview 4.2 Treatment Overview 4.3 Treatment Guidelines and Leading Prescribed Drugs 4.4 5EU 5 Competitive Assessment 5.1 Overview 5.2 Product Profiles - Major Brands 5.3 Other Therapeutic Classes 6 Unmet Need and Opportunity 6.1 Overview 6.2 Effective Treatment Options for Bipolar Depression 6.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes 6.4 Mood Stabilizers with Improved Safety Profiles 6.5 Education for Physicians in Order to Improve Diagnosis Rates 6.6 Novel Drugs Developed Specifically for Bipolar Disorder 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 7.3 Off-label Pipeline and Recently Approved Therapies 7.4 Promising Drugs in Early-Stage Development 7.5 Other Drugs in Development 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/24zvmw/bipolar_disorder
View source version on businesswire.com: http://www.businesswire.com/news/home/20160628005709/en/ |
